“This partnership is part of an ongoing strategy of X-Chem to work with venture investors to establish strategic collaborations with their newly formed portfolio companies,” said Steffen Helmling, VP of Business Development for X-Chem. “ZebiAI represents the sixth company that has been established using X-Chem’s products and technologies as a cornerstone. We look forward to supporting ZebiAI’s efforts to identify novel targets and drug candidates on a broad scale.”
ZebiAI Therapeutics, Inc. is a newly established company, founded by X-Chem co-founder and CEO Richard Wagner. The organization is focused on the application of machine learning technologies to aid the discovery of chemical probes for researchers in academia and industry and on the exploration of artificial intelligence to accelerate the discovery of clinical candidate compounds. The collaboration with X-Chem provides for the broad utilization of the DEL platform for hundreds to thousands of screens during the term of the agreement.
“We are excited to work with ZebiAI Therapeutics using our highly differentiated DEX platform,” said Matt Clark, SVP of Chemistry at X-Chem. “To date, we have generated well over 70 licensed programs for our partners, and we look forward to dramatically increase that number through the ZebiAI relationship.”
Brant Binder, President of ZebiAI Therapeutics stated: “Through this agreement, we have the opportunity to unlock novel biology to tackle the most difficult diseases. We are excited to partner with X-Chem and our investors from Anterra Capital as we surge ahead with our Chemome Initiative.”
X- Chem, Inc. is a privately-owned biotechnology company based in Waltham, Massachusetts. The company’s mission is to apply its powerful product engine to the discovery of small molecule leads against high-value therapeutic targets.